SEC Company Response from NeuBase Therapeutics, Inc. (CIK 0001173281) — Jul 2, 2021
NeuBase Therapeutics, Inc. (CIK 0001173281)
Date: July 2, 2021 · CIK: 0001173281 · Accession: 0001104659-21-088852
AI Filing Summary & Sentiment
File numbers found in text: 333-257327
Letter
NeuBase Therapeutics, Inc.
350 Technology Drive
Pittsburgh, PA 15219
July 2, 2021
VIA EDGAR
Securities and Exchange Commission
100 F Street, NE
Washington, D.C. 20549-0406
Re: NeuBase Therapeutics, Inc.
Registration Statement on Form S-3, filed June 23, 2021
File No. 333-257327
Ladies and Gentlemen:
Pursuant to Rule 461 under the Securities Act of 1933, as amended, NeuBase Therapeutics, Inc. (the “Company”) hereby requests that the effectiveness of the Registration Statement on Form S-3 (Registration No. 333-257327) of the Company (the “Registration Statement”), filed with the Securities and Exchange Commission (the “Commission”) on June 23, 2021, be accelerated so that such Registration Statement shall become effective at 4:30 p.m. (Eastern Time) on July 7, 2021, or as soon as possible thereafter. There are no underwriters for this proposed offering, which is an offering of the Company’s common stock by a selling stockholder.
The Company hereby confirms that it is aware of its responsibilities under the Securities Act of 1933, as amended, and the Securities Exchange Act of 1934, as amended, as they relate to the proposed offering of the securities specified in the Registration Statement.
It would be appreciated if, promptly after the Registration Statement has become effective, you would so inform our outside counsel, Jeffrey T. Hartlin of Paul Hastings LLP, by telephone at (650) 320-1804 or by email at jeffhartlin@paulhastings.com. The Company hereby authorizes Mr. Hartlin to orally modify or withdraw this request for acceleration.
Sincerely,
NEUBASE THERAPEUTICS, INC.
Show Raw Text
CORRESP
1
filename1.htm
NeuBase
Therapeutics, Inc.
350 Technology Drive
Pittsburgh, PA 15219
July 2, 2021
VIA EDGAR
Securities and Exchange Commission
100 F Street, NE
Washington, D.C. 20549-0406
Re: NeuBase Therapeutics, Inc.
Registration
Statement on Form S-3, filed June 23, 2021
File No. 333-257327
Ladies and Gentlemen:
Pursuant
to Rule 461 under the Securities Act of 1933, as amended, NeuBase Therapeutics, Inc. (the “Company”) hereby
requests that the effectiveness of the Registration Statement on Form S-3 (Registration No. 333-257327) of the Company (the “Registration
Statement”), filed with the Securities and Exchange Commission (the “Commission”) on June 23,
2021, be accelerated so that such Registration Statement shall become effective at 4:30 p.m. (Eastern Time) on July 7, 2021, or as soon
as possible thereafter. There are no underwriters for this proposed offering, which is an offering of the Company’s common stock
by a selling stockholder.
The
Company hereby confirms that it is aware of its responsibilities under the Securities Act of 1933, as amended, and the Securities Exchange
Act of 1934, as amended, as they relate to the proposed offering of the securities specified in the Registration Statement.
It
would be appreciated if, promptly after the Registration Statement has become effective, you would so inform our outside counsel, Jeffrey
T. Hartlin of Paul Hastings LLP, by telephone at (650) 320-1804 or by email at jeffhartlin@paulhastings.com. The Company hereby authorizes
Mr. Hartlin to orally modify or withdraw this request for acceleration.
Sincerely,
NEUBASE THERAPEUTICS, INC.
By:
/s/ Sam Backenroth
Sam Backenroth
Chief Financial Officer, Treasurer and Secretary
cc:
Jeffrey
T. Hartlin, Paul Hastings LLP